Bristol-Myers Squibb (BMY) closed at $59.83 on Oct 16, 2026, down 1.2% on the day. The stock is down 4.8% over the past month, down 0.5% over three months, up 13.4% year to date and up 40.3% over the past year. It trades 12.8% below its 52-week high of $68.64 and 43.9% above its 52-week low of $41.59. The close sits below its 50-day moving average ($63.51) and above its 200-day moving average ($59.43).
NextPick tracks BMY in its Pharma basket alongside JNJ, ABBV, MRK, RHHBY and NVS. As of Oct 16, 2026, the basket's money-flow score is -5 (neutral), and the basket is up 3.1% over five sessions. Over the past month BMY ranks 10th of 12 basket members by price change.
BMY is scheduled to report earnings on Oct 29, 2026. Over its last 8 reports the stock moved an average of 4.3% on the first trading day after earnings, beating the options-implied move in 4 of 8.
BMY options were pricing 36% at-the-money implied volatility on Oct 7, 2026, an IV rank of 73 over the past year.
Bristol-Myers Squibb is scheduled to report on Oct 29, 2026.
Over the last 8 reports, BMY moved an average of 4.3% on the first trading day after earnings. The move beat the options-implied move in 4 of 8 reports.
Yes — the Oct 16, 2026 close of $59.83 is 0.7% above the 200-day average of $59.43.
BMY closed 12.8% below its 52-week high of $68.64.
NextPick groups BMY with JNJ, ABBV, MRK, RHHBY and NVS in its Pharma basket.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
